• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

MIV-711 effective in reducing bone and cartilage manifestations for patients with osteoarthritis

byThomas SuandDeepti Shroff Karhade
January 3, 2020
in Chronic Disease, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this double-blind phase 2a trial, cathepsin K inhibitor MIV-711 did not show a significant benefit in reducing pain but proved effective in delaying structural changes associated with progression of osteoarthritis.

2. Biomarkers of bone resorption were significantly reduced in both treatment groups but returned to baseline levels after treatment stopped at the end of the study.

Evidence level: 1 (Excellent)

Study Rundown: Cathepsin K is a cysteine endopeptidase with the ability to degrade bone and cartilage through catabolism of essential matrix proteins including elastin, collagen, and gelatin. Progression of osteoarthritis is marked by such structural changes, but the effects of cathepsin K inhibition with relation to this condition are yet unknown. MIV-711 is a selective, reversible inhibitor that has substantially reduced biomarkers of bone resorption and cartilage loss in preclinical modeling and clinical testing. This study aimed to determine the efficacy, safety, and tolerability of MIV-711 in patients with symptomatic osteoarthritis, finding that while there was no significant difference versus placebo in patient-reported pain, function, and stiffness, patients in the treatment groups experienced significant reductions in cartilage thinning, bone area progression, and relevant biomarkers. Withdrawal of MIV-711 at the end of the study was associated with a noticeable rebound effect, supporting effective target engagement of the bone-acting agent. Adverse events occurred at similar rates across groups, and no serious adverse events were considered to be treatment-related. Patient adherence was high, but this study was limited by a short time frame that may have precluded the translation of disease-modifying effects to alleviation of symptoms.

Click here to read the study in Annals of Internal Medicine

Click here to read an accompanying editorial in Annals of Internal Medicine

Relevant Reading: Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

RELATED REPORTS

Knee extensor muscle weakness may be a risk factor for osteoarthritis

Wellness Check: Exercise

Platelet-rich plasma injections did not significantly improve ankle symptoms compared to placebo in patients with ankle osteoarthritis

In-Depth [randomized controlled trial]: In this 26-week, double-blind, multicenter phase 2a trial, 244 patients in Europe aged 40 to 80 years with primary knee osteoarthritis were randomly assigned in a 1:1:1 ratio to receive 100 mg MIV-711, 200 mg MIV-711, or placebo once daily. Exclusion criteria were inflammatory arthritis, corticosteroid use, hyaluronic acid use, significant injury, surgery, and joint replacement. The primary outcome of average pain severity decreased in all treatment groups according to change in numerical rating scale (NRS) score, but no statistically significant difference in least-squares means was found (-1.4 [95% CI, 1.9 to 0.8] for placebo; 1.7 [CI, 2.3 to 1.2] for MIV-711, 100 mg/d; and 1.5 [CI, 2.0 to 0.9] for MIV-711, 200 mg/d). Conversely, bone area on MRI increased in all groups, but the estimated mean changes were significantly smaller in the two treatment groups (23.3 sq. mm [CI, 15.7 to 30.9 sq. mm] for placebo; 7.9 sq. mm [CI, 0.5 to 15.3 sq. mm] for MIV-711, 100 mg/d; and 8.6 sq. mm [CI, 1.1 to 16.1 sq. mm] for MIV-711, 200 mg/d). Levels of types I and II collagen C-telopeptide were reduced by 27.8% and 34.4%, respectively, with 100 mg/d MIV-711 and by 50.3% and 51.6% with 200 mg/d MIV-711, but returned to baseline levels after cessation of treatment (P<.001 for all).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bonecartilagecathepsin K inhibitorMIV-711osteoarthritis
Previous Post

#VisualAbstract: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent

Next Post

#VisualAbstract: Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants

RelatedReports

Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

Knee extensor muscle weakness may be a risk factor for osteoarthritis

February 2, 2022
Adolescents’ muscle strength associated with lower cardiometabolic risk
Wellness

Wellness Check: Exercise

January 27, 2022
Social networks play key roles in parental vaccination decisions
Rheumatology

Platelet-rich plasma injections did not significantly improve ankle symptoms compared to placebo in patients with ankle osteoarthritis

October 28, 2021
Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

Web-based intervention of self-directed strengthening exercises improved pain and functional capacity for patients with osteoarthritis

April 23, 2021
Next Post
#VisualAbstract: Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants

#VisualAbstract: Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants

#VisualAbstract: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X)

#VisualAbstract: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X)

Poor olfaction linked to increased mortality in older adults

Levothyroxine not effective for treatment of subclinical hypothyroidism symptoms in geriatric patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.